Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
25.11
+0.25 (1.01%)
Jun 4, 2026, 12:20 PM EDT - Market open
Maze Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Maze Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $62.55. The average 1-year stock price forecast is 149.10% higher than the current stock price, while the lowest is $46 (+83.19%) and the highest is $110 (+338.07%).
Price Target: $62.55 (+149.10%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Maze Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 11 | 11 | 11 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Maintains $58 → $53 | Buy | Maintains | $58 → $53 | +111.07% | May 23, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $110 | Buy | Maintains | $110 | +338.07% | May 20, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $57 | Buy | Maintains | $57 | +127.00% | May 16, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 14, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $55 | Buy | Maintains | $55 | +119.04% | May 14, 2026 |
Financial Forecast
Revenue This Year
15.30M
Revenue Next Year
3.81M
from 15.30M
Decreased by -75.13%
EPS This Year
-2.87
from -3.05
EPS Next Year
-3.43
from -2.87
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 21.0M | 22.1M | ||||||
| Avg | 15.3M | 3.8M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 44.1% | ||||||
| Avg | - | -75.1% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.31 | -2.80 | ||||||
| Avg | -2.87 | -3.43 | ||||||
| Low | -3.30 | -4.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.